Senti Biosciences Holdings (SNTI) Income from Continuing Operations (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Income from Continuing Operations of 117357000.0 for Q4 2025, down 19.9% year-over-year from 146522219.78 in Q4 2024, and down 341.37% quarter-over-quarter from 26589000.0 in Q3 2025.
Senti Biosciences Holdings (SNTI) Income from Continuing Operations (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 117357000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 19.9% year-over-year to 117357000.0; the TTM figure through Dec 2025 stood at 223939000.0 (up 12.23% YoY), while the FY2025 annual figure was 167500000.0, down 17.34% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 117357000.0, down from 26589000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1178.0 in Q1 2021, with the low at 117357000.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 60606000.0 (2022), against an average of 54131910.7.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations plunged 996066.21% in 2022, then jumped 71.72% in 2024.
- Senti Biosciences Holdings' Income from Continuing Operations stood at 33567088.0 in 2021, then tumbled by 75.31% to 58845000.0 in 2022, then slumped by 35.87% to 79951000.0 in 2023, then slipped by 22.42% to 97875000.0 in 2024, then declined by 19.9% to 117357000.0 in 2025.
- Business Quant data shows SNTI's Income from Continuing Operations at 117357000.0 in Q4 2025, 26589000.0 in Q3 2025, and 58446000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | -14.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -117.36 Mn |
| Sep 30, 2025 | -26.59 Mn |
| Jun 30, 2025 | -58.45 Mn |
| Mar 31, 2025 | -21.55 Mn |
| Dec 31, 2024 | -97.88 Mn |
| Sep 30, 2024 | -27.79 Mn |
| Jun 30, 2024 | -62.37 Mn |
| Mar 31, 2024 | -67.11 Mn |
| Dec 31, 2023 | -79.95 Mn |
| Sep 30, 2023 | -98.26 Mn |
| Jun 30, 2023 | -71.35 Mn |
| Mar 31, 2023 | -72.87 Mn |
| Dec 31, 2022 | -58.85 Mn |
| Sep 30, 2022 | -74.42 Mn |
| Jun 30, 2022 | -82.14 Mn |
| Mar 31, 2022 | -11.73 Mn |
| Dec 31, 2021 | -33.57 Mn |
| Sep 30, 2021 | -11.42 Mn |
| Jun 30, 2021 | -9.00 Mn |
| Mar 31, 2021 | -1,178.00 |